250 related articles for article (PubMed ID: 37101607)
1. Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery.
Espinoza-Chávez RM; Salerno A; Liuzzi A; Ilari A; Milelli A; Uliassi E; Bolognesi ML
ACS Bio Med Chem Au; 2023 Feb; 3(1):32-45. PubMed ID: 37101607
[TBL] [Abstract][Full Text] [Related]
2. Novel approaches to targeted protein degradation technologies in drug discovery.
Xue Y; Bolinger AA; Zhou J
Expert Opin Drug Discov; 2023 Apr; 18(4):467-483. PubMed ID: 36895136
[TBL] [Abstract][Full Text] [Related]
3. Targeted protein degradation: A promise for undruggable proteins.
Samarasinghe KTG; Crews CM
Cell Chem Biol; 2021 Jul; 28(7):934-951. PubMed ID: 34004187
[TBL] [Abstract][Full Text] [Related]
4. PROteolysis-Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives.
Vicente ATS; Salvador JAR
MedComm (2020); 2024 Jun; 5(6):e575. PubMed ID: 38845697
[TBL] [Abstract][Full Text] [Related]
5. Expanding the horizons of targeted protein degradation: A non-small molecule perspective.
Huang X; Wu F; Ye J; Wang L; Wang X; Li X; He G
Acta Pharm Sin B; 2024 Jun; 14(6):2402-2427. PubMed ID: 38828146
[TBL] [Abstract][Full Text] [Related]
6. A rapid and accurate method for evaluating the degradation of pan-Akt in cells by PROTACs using NanoLuc luciferase.
Ji X; Miao L; Wu Y; Zhao T; Si Y; Tan X; Zhou Q; Zuo R; Pei J; Wu J; Ma C; Ma Z; Xu D
Biol Methods Protoc; 2024; 9(1):bpae014. PubMed ID: 38544761
[TBL] [Abstract][Full Text] [Related]
7. Exosome-mediated PROTAC delivery for treatment of RNA viral infections and zoonoses.
Mukerjee N; Maitra S; Ghosh A; Alexiou A; Thorat ND
Drug Discov Today; 2024 May; ():104044. PubMed ID: 38796097
[TBL] [Abstract][Full Text] [Related]
8. Advances in Targeted Therapies for Inflammatory Diseases and Cancer: Exploring Cellular Mechanisms and Therapeutic Strategies.
Kargbo RB
ACS Med Chem Lett; 2024 Jun; 15(6):758-760. PubMed ID: 38894902
[TBL] [Abstract][Full Text] [Related]
9. Expanding TPD Horizons: Innovative Strategies Targeting BCL6 and SMARCA2.
Kargbo RB
ACS Med Chem Lett; 2024 May; 15(5):576-578. PubMed ID: 38746879
[TBL] [Abstract][Full Text] [Related]
10. Antiviral PROTACs: Opportunity borne with challenge.
Liang J; Wu Y; Lan K; Dong C; Wu S; Li S; Zhou HB
Cell Insight; 2023 Jun; 2(3):100092. PubMed ID: 37398636
[TBL] [Abstract][Full Text] [Related]
11. PROTACs: A novel strategy for cancer drug discovery and development.
Han X; Sun Y
MedComm (2020); 2023 Jun; 4(3):e290. PubMed ID: 37261210
[TBL] [Abstract][Full Text] [Related]
12. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
Sincere NI; Anand K; Ashique S; Yang J; You C
Molecules; 2023 May; 28(10):. PubMed ID: 37241755
[TBL] [Abstract][Full Text] [Related]
13. Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier.
Tashima T
Antibodies (Basel); 2023 Jun; 12(3):. PubMed ID: 37489365
[TBL] [Abstract][Full Text] [Related]
14. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD).
Wang H; Zhou R; Xu F; Yang K; Zheng L; Zhao P; Shi G; Dai L; Xu C; Yu L; Li Z; Wang J; Wang J
Biomater Res; 2023 Jul; 27(1):72. PubMed ID: 37480049
[TBL] [Abstract][Full Text] [Related]
15. PROTACs in the Management of Prostate Cancer.
Yedla P; Babalghith AO; Andra VV; Syed R
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175108
[TBL] [Abstract][Full Text] [Related]
16. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy.
Gao J; Yang L; Lei S; Zhou F; Nie H; Peng B; Xu T; Chen X; Yang X; Sheng C; Rao Y; Pu K; Jin J; Xu Z; Yu H
Sci Bull (Beijing); 2023 May; 68(10):1069-1085. PubMed ID: 37169612
[TBL] [Abstract][Full Text] [Related]
17. Proximity-Based Modalities for Biology and Medicine.
Liu X; Ciulli A
ACS Cent Sci; 2023 Jul; 9(7):1269-1284. PubMed ID: 37521793
[TBL] [Abstract][Full Text] [Related]
18. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.
Bhole RP; Kute PR; Chikhale RV; Bonde CG; Pant A; Gurav SS
Bioorg Chem; 2023 Oct; 139():106720. PubMed ID: 37480814
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with
Li P; Jia C; Fan Z; Hu X; Zhang W; Liu K; Sun S; Guo H; Yang N; Zhu M; Zhuang X; Xiao J; Zheng Z; Li S
Acta Pharm Sin B; 2023 Jun; 13(6):2715-2735. PubMed ID: 37425039
[TBL] [Abstract][Full Text] [Related]
20. Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog pathway inhibitor-1.
Bagka M; Choi H; Héritier M; Schwaemmle H; Pasquer QTL; Braun SMG; Scapozza L; Wu Y; Hoogendoorn S
Nat Commun; 2023 Jul; 14(1):3893. PubMed ID: 37393376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
